Baird Medical Stock Price, News & Analysis

Baird Medical (NASDAQ: BDMD) has received the 'Most Valuable Investment Award' at the 10th China Medical Industry Innovation Competition for its innovative AI Tumor Ablation Surgical Robot. The system integrates multimodal AI algorithms with high-precision robotic arm control, featuring autonomous decision-making and dynamic optimization capabilities.

Key technological advantages include:

• Integration of over 100,000 tumor ablation image cases and 50,000 pathology reports
• Federated learning technology enabling secure global data sharing
• Future quantum-optimized pretraining capabilities

The project combines expertise from Nanyang Technological University, oncologic surgeons, and AI engineers from the Chinese Academy of Sciences, with over 90 filed patents. The system will undergo clinical simulations across 20 top-tier hospitals globally and includes an AI-powered surgical ethics decision module targeting surgical complications below 1%. Applications extend beyond tumor ablation to neurosurgery and urology, with planned regulatory approvals in 30+ countries.

Baird Medical Investment Holdings (NASDAQ: BDMD) has secured regulatory approval from the Indonesian Ministry of Health for its microwave ablation (MWA) technology. The approval covers two key products: the Great Wall Microwave Therapeutic Instrument and the Great Wall Disposable Microwave Ablation Needle.

The company's MWA technology is a minimally invasive procedure that uses targeted microwave energy to destroy abnormal tissue while minimizing impact on surrounding areas. This technology is particularly effective in treating thyroid nodules and tumors, offering benefits such as enhanced precision and faster recovery times.

Following this regulatory milestone, Baird Medical plans to expand its distribution network and collaborate with medical institutions across Indonesia, advancing its global strategic expansion in emerging markets.

Baird Medical (NASDAQ: BDMD), a medical device company specializing in AI-powered surgical robotics and microwave ablation (MWA) technology, showcased its innovations at the 2025 North American Society of Interventional Endocrinologists (NASOIE) Annual Meeting in Lehi, Utah.

The company's booth attracted significant physician interest, featuring hands-on thyroid phantom demonstrations that highlighted their MWA technology's precision, safety, and efficiency. Company experts engaged with attendees in detailed discussions about clinical applications and practical insights regarding MWA in thyroid care.

The event, which focuses on advancing minimally invasive treatments for thyroid and parathyroid disorders, provided Baird Medical an opportunity to reinforce its position in next-generation thyroid ablation therapies. The company plans to utilize insights gained from NASOIE 2025 to further enhance its MWA technology for thyroid treatment solutions.

Baird Medical Investment Holdings (NASDAQ: BDMD) hosted a delegation of Bangladeshi physicians at its Guangzhou headquarters for an expert-led microwave ablation (MWA) training program. The delegation included four doctors who participated in theoretical discussions and hands-on demonstrations at Baird's facility.

The training continued at Sun Yat-sen University Cancer Center, where participants observed live MWA procedures for liver and lung ablations, followed by discussions with specialists. The program concluded with a session on thyroid microwave ablation techniques led by Dr. Feng Han in the hospital's Ultrasound Department.

Chairwoman Haimei Wu emphasized the company's commitment to global knowledge-sharing and medical innovation through cross-border collaboration.

Baird Medical Investment Holdings (NASDAQ: BDMD) recently supported a specialized microwave ablation (MWA) training program at the Columbia Thyroid Center in New York City. The two-day course, led by Dr. Jennifer Kuo, Director of the Interventional Endocrinology Program, provided comprehensive instruction on MWA techniques, safety, and clinical applications.

The training attracted physicians from the US and Mexico, including Dr. Hosai Todd-Hesham and Dr. Camilo González Velázquez. Participants engaged in hands-on training with thyroid models and observed three live procedures, including the successful ablation of a 5cm thyroid nodule. The program focused on device operation, ablation precision, and real-time procedural adjustments.

This initiative is part of Baird Medical's commitment to expanding its global MWA education network and accelerating the adoption of minimally invasive treatments through standardized training and collaboration.

Baird Medical (NASDAQ: BDMD) made a notable presence at the 2025 North American Society for Interventional Thyroidology (NASIT) conference, showcasing its advanced microwave ablation (MWA) technology for thyroid treatment. The company's exhibit generated significant interest, facilitating meaningful discussions with healthcare professionals about minimally invasive thyroid therapies.

A key highlight was a keynote presentation by Dr. Emad Kandil from Tulane University School of Medicine, who presented case studies and clinical data demonstrating MWA's advantages, including reduced procedure times, fewer complications, and improved patient outcomes. The presentation garnered substantial attention and sparked engaging discussions, underlining the industry's interest in MWA technology.

Through the conference, Baird Medical reinforced its position in advancing patient care through innovation and strengthened its collaborations with medical professionals in the field of minimally invasive thyroid treatments.

Baird Medical (NASDAQ: BDMD), a leader in microwave ablation technology, participated in the 2025 Microcap Conference at the Borgata Hotel in Atlantic City. The event, which attracted over 750 institutional investors and industry experts, served as a platform for the company to showcase its minimally invasive microwave ablation technology and discuss its recent FDA 510(k) clearance for the U.S. market.

During the conference, Baird Medical's leadership team conducted one-on-one meetings with investors to outline U.S. market penetration strategies and engaged in discussions about potential mergers and acquisitions. Chairwoman Haimei Wu emphasized the conference's role in connecting with global investors and identifying collaboration opportunities. The company plans to leverage these insights to advance its global expansion while continuing investments in research and development.

Baird Medical Investment Holdings (NASDAQ: BDMD) marked a transformative year in 2024, highlighted by its successful Nasdaq listing on October 2. The company, specializing in Microwave Ablation (MWA) technology, secured multiple patents enhancing MWA technology and production efficiency.

Key achievements include obtaining a Class III Medical Device Production License in China and receiving notable industry recognition, including designation as a Jiangsu Province High-Tech Enterprise. The company's subsidiary, Nanjing Great Wall, strengthened its position with four new patents focused on vascular thermal coagulation and RF ablation catheter optimization.

Nanjing Great Wall also secured a Class III Medical Device Registration Certificate in China for its Disposable Microwave Ablation Needle and obtained ISO 13485 certification, enhancing its international market access. These developments position Baird Medical for continued global expansion and advancement in minimally invasive treatment solutions.

Baird Medical Investment Holdings (NASDAQ: BDMD) has announced its participation in the 2025 North American Society for Interventional Thyroidology (NASIT) Conference, scheduled for January 31 – February 1, 2025, in Washington, D.C. The company, known for its leadership in Minimally Invasive Microwave Ablation (MWA) technology, will return to this premier thyroid interventions forum.

During the conference, Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, will present at the Product Theater, following his achievement of completing 100 MWA cases. The event provides Baird Medical with opportunities to engage with global experts, industry leaders, and potential partners while contributing to discussions on MWA technology advancements.

The company aims to gain insights into industry trends, optimize strategic initiatives, and continue driving innovation in global healthcare through this participation.